ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 390

Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

Hanna Kim1, Samantha Dill 2, Michelle O'Brien 2, Minal Jain 3, Shajia Lu 4, Wanxia Tsai 4, Yinghui Shi 5, Laura Vian 4, Massimo Gadina 4, Michelle Millwood 2, April Brundidge 2, Lisa G. Rider 6 and Robert Colbert 1, 1Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, 2Pediatric Clinical Trials Unit (PCTU), Office of the Clinical Director, NIAMS, NIH, Bethesda, MD, 3Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, 4Translational Immunology Section, NIAMS, NIH, Bethesda, MD, 5Office of Clinical Director, NIAMS, NIH, Bethesda, MD, 6Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: clinical trials, Janus kinase (JAK), juvenile dermatomyositis, myositis and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: Muscle Biology, Myositis & Myopathies Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications. In a compassionate use program, we assessed efficacy and safety of baricitinib (JAK 1/2 inhibitor) in active refractory JDM.

Methods: Active (based on ≥3 core set measures (CSM)) and refractory (use of high dose steroids and ≥2 other medications, including ≥1 biologic therapy) patients with JDM were enrolled after washing out biologic agents other than IVIG. Baricitinib was dosed based on weight and renal function. Primary outcome was reduction in symptom daily diary score (DDS) of weakness, fatigue, musculoskeletal pain, and rash. Other assessments included International Myositis Assesment and Clinical Studies (IMACS) disease activity CSMs and Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). Peripheral 28 gene inteferon-regulated gene (IRG) score and serum CXCL10 (IP-10) were assessed. Paired t-test was used to compare baseline to 24 weeks. Safety and tolerability were also assessed.

Results: Four JDM patients (5.8-20.7 years old) were enrolled (NCT01724580).Patients received baricitinib 4-8 mg/day PO divided BID. After 24 weeks, DDS reduced from a mean of 2.0 (range 1.1-2.3) to 1.0 (0.7-1.1; mean decrease 49%, p=0.02) (Figure or Fig 1A). Physician global activity visual analog scale (VAS) decreased from a mean of 5.1 (3.5-7.4) to 3.9 (3.0-6.1; 24% decrease, p=0.04) (Fig 1B). Extramuscular global activity VAS decreased from mean 5.1 (3.0-7.3) to 3.6 (1.0-5.0; mean 34% decrease, p=0.03). CDASI activity score reduced from mean 43 (27-53) to 26 (14-48; mean improvement 41%, p=0.04) (Fig 1C). In 2/4 with baseline weakness, manual muscle testing (MMT8) increased from 108 to 135 and 116 to 142 (mean improvement 24%) (Fig 1D). By the ACR-EULAR JDM response criteria, the Total Improvement Score (TIS) was mean 39, range 17.5-62.5. In 2 pts with baseline weakness, the TIS improved moderately, with a change of 55 and 62.5. Two patients reduced prednisone (21 to 15 and 10 to 7.5 mg/day); 2 patients’ doses remained unchanged (5 and 10 mg/day). Baricitinib was generally well tolerated. One patient had an increase in plasma BK viral titer; the other 3 patients were negative for BK virus in blood and urine. No adverse events required holding/discontinuing baricitinib. IRG score was significantly lower at 24 weeks (p value < 0.01) and serum IP-10 at 12 weeks was trending lower (p= 0.056).

Conclusion: Preliminary data on the use of baricitinib (JAK 1/2 inhibitor) in 4 refractory JDM patients are encouraging, showing improvement in symptom DDS as well as in validated measures of rash (4/4) and strength (2/2 with baseline weakness), and other CSMs. Patients with baseline weakness met clinically significant moderate improvement by the ACR-EULAR response criteria. A corresponding decrease in IRG and trend down in IP-10 was observed. Baricitinib was generally well tolerated and further evaluation in JDM should be considered.

Disclosures: Baricitinib provided by Eli Lilly and Company, expanded access program sponsor. Other support: IRP of NIH, NIAMS, NIEHS, CC.


Figure 1

Clinical outcomes are shown at baseline -week or wk 0-, and then at week 4, 8, 12, and 24 for -A- mean daily diary score -DDS- out of 4 -B- Physician Global Activity -PGA- out of 10, -C- Cutaneous Dermatomyositis Disease Area and Severity -CDASI- Activity Score out of 100, and -D- Manual Muscle Testing-8 out of 150.


Disclosure: H. Kim, Cure JM Foundation, 2; S. Dill, None; M. O'Brien, None; M. Jain, None; S. Lu, None; W. Tsai, None; Y. Shi, None; L. Vian, None; M. Gadina, None; M. Millwood, None; A. Brundidge, None; L. Rider, ., 2, 9, aTyr, 9, Bristol Myers Squibb, 2, Cure JM Foundation, 2, 9, Eli Lilly and Company, 9, Hope Pharmaceuticals, 2, Lilly-drug, 9, MedImmune / AstraZeneca, 9, MedImmune/AstraZeneca, 9, NIEHS, 2, NIEHS, NIH, 2, NIH, 2; R. Colbert, Eli Lilly and Company, 2, 9.

To cite this abstract in AMA style:

Kim H, Dill S, O'Brien M, Jain M, Lu S, Tsai W, Shi Y, Vian L, Gadina M, Millwood M, Brundidge A, Rider L, Colbert R. Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/preliminary-response-to-janus-kinase-jak-inhibition-with-baricitinib-in-refractory-juvenile-dermatomyositis/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preliminary-response-to-janus-kinase-jak-inhibition-with-baricitinib-in-refractory-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences